



T +31 30 785 63 74
m.lindenberg@vo.eu

Marthe Lindenberg

Life Sciences

Dutch Patent Attorney

Associate

Marthe Lindenberg obtained a Bachelor's and Master's degree in Biomedical Sciences at Utrecht University. During the Master-phase, she did research internships in the UMC Utrecht and at the University of California, San Francisco. Having specialized in Infection and Immunity, she continued her studies with a PhD track at Utrecht University and the Wilhelmina Children's Hospital, where she studied the immune-modulatory functions of immune-cell-derived extracellular vesicles. In 2019 she started at V.O. She obtained her PhD in November 2019.

Working experience

- Patent Attorney, V.O. (September 2022)
- Trainee Patent Attorney, V.O. (2019-present)
- PhD University of Utrecht (2014-2018)

Education

- PhD Infection and Immunity, University of Utrecht (2019)
- MSc Infection and Immunity, University of Utrecht (2014)
- BSc Biomedical Sciences, University of Utrecht (2012)

Publications

- M. Mues, L. Karra, D. Romero-Moya, A. Wandler, M. J. Hangauer, O. Ksionda, Y. Thus, M.F.S. Lindenberg, K. Shannon, M. T. McManus, J. P. Roose. "High-complexity shRNA libraries and PI3 kinase inhibition in cancer: high-fidelity synthetic lethality predictions". Cell Reports 2019
- M.F.S. Lindenberg, D.G.J. Koerhuis, E.G.F. Borg, E.M. van 't Veld, T.A.P. Driedonks, R. Wubbolts, W. Stoorvogel, M. Boes. "Bystander T-cells support clonal T-cell activation by controlling the release of dendritic cell-derived immune-stimulatory extracellular vesicles". Front. Imm. 2019
- M.F.S. Lindenberg, W. Stoorvogel. "Antigen presentation by extracellular vesicles from professional antigen-presenting cells". Annu. Rev. Immunol. 2018
- A.M. Gram, T. Oosenbrug, M.F.S. Lindenberg, C. Büll, A. Comvalius, K.J.I. Dickson, J. Wiegant, H. Vrolijk, R.J. Lebbink, R. Wolterbeek, G.J. Adema, M. Griffioen, M.H.M. Heemskerk, D.C. Tschärke, L. M. Hutt-Fletcher, E.J.H.J. Wiertz, R.C. Hoeben, M.E. Rensing. "The Epstein-Barr virus glycoprotein gp150 forms an immune-evasive glycan shield at the surface of infected cells". PLoS Path. 2016
- M. van Gent, A.M. Gram, I.G.J. Boer, R.J. Geerdink, M.F.S. Lindenberg, R.J. Lebbink, E.J. Wiertz, M.E. Rensing. "Silencing the shutoff protein of Epstein-Barr virus in productively infected B cells points to (innate) targets for immune evasion". J. Gen. Virol. 2015.

Languages

- Dutch
- English